Elixir Medical

May 28th, 2023 - 04:22 GMT

Clinical data demonstrates DynamX Bioadaptor restores Vessel Motion and Function with better effectiveness at 12 Months compared to a leading Drug-Eluting Stent (DES)

Elixir Medical, a developer of breakthrough cardiovascular technologies with a strong presence in the Middle East market, today announced that the large international randomized BIOADAPTOR RCT trial of the company’s DynamX® Coronary Drug-Eluting Bioadaptor compared to Resolute OnyxTM Drug-Eluting Stent met its primary endpoint of Target Lesion Failure (TLF) non-inferiority at 12 months. DynamX Bioadaptor is a new type of coronary implant designed to unlock the scaffold, uncage the vessel, to return normal vessel motion and function after percutaneous coronary intervention (PCI), with continued dynamic support of the atherosclerotic vessel ...

Elixir Medical

Contact Information

Elixir Medical latest

Clinical data demonstrates DynamX Bioadaptor restores Vessel Motion and Function with better effectiveness at 12 Months compared to a leading Drug-Eluting Stent (DES)